
==== Front
World J Psychiatry
WJP
World Journal of Psychiatry
2220-3206
Baishideng Publishing Group Inc

jWJP.v14.i9.pg1346
10.5498/wjp.v14.i9.1346
96852
Observational Study
Expression level of myocardial enzymes in patients with schizophrenia: Predictive value in the occurrence of violence
He WM et al. Value of myocardial enzymes in violence
He Wei-Min Department of Rehabilitation Ward, Shaoxing Seventh People's Hospital, Shaoxing 312000, Zhejiang Province, China

Zhang Xin-Yuan Department of Laboratory, Shaoxing Seventh People's Hospital, Shaoxing 312000, Zhejiang Province, China

Xie Wei-Gen Department of Medical, Shaoxing Seventh People's Hospital, Shaoxing 312000, Zhejiang Province, China

Lv Dan-Ping Department of Laboratory, Shaoxing Seventh People's Hospital, Shaoxing 312000, Zhejiang Province, China

Shen Qun-Di Department of General Affairs, Shaoxing Seventh People's Hospital, Shaoxing 312000, Zhejiang Province, China. shenqundi@163.com

Author contributions: Shen QD was the guarantor and designed the study; He WM and Zhang XY participated in the acquisition, analysis, interpretation of the data, and drafted the initial manuscript; Lv DP and Xie WG revised the article critically for important intellectual content; all authors contributed to the article and approved the submitted version.

Supported by The Shaoxing Science and Technology Plan Project Plan, No. 2022A14002 .

Corresponding author: Qun-Di Shen, MBBS, Associate Chief Technician, Department of General Affairs, Shaoxing Seventh People's Hospital, No. 1234 Shengli West Road, Yuecheng District, Shaoxing 312000, Zhejiang Province, China. shenqundi@163.com

19 9 2024
19 9 2024
14 9 13461353
15 7 2024
13 8 2024
27 8 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
BACKGROUND

Schizophrenic patients are prone to violence, frequent recurrence, and difficult to predict. Emotional and behavioral abnormalities during the onset of the disease, resulting in active myocardial enzyme spectrum.

AIM

To explored the expression level of myocardial enzymes in patients with schizophrenia and its predictive value in the occurrence of violence.

METHODS

A total of 288 patients with schizophrenia in our hospital from February 2023 to January 2024 were selected as the research object, and 100 healthy people were selected as the control group. Participants’ information, clinical data, and laboratory examination data were collected. According to Modified Overt Aggression Scale score, patients were further divided into the violent (123 cases) and non-violent group (165 cases).

RESULTS

The comparative analysis revealed significant differences in serum myocardial enzyme levels between patients with schizophrenia and healthy individuals. In the schizophrenia group, the violent and non-violent groups also exhibited different levels of serum myocardial enzymes. The levels of myocardial enzymes in the non-violent group were lower than those in the violent group, and the patients in the latter also displayed aggressive behavior in the past.

CONCLUSION

Previous aggressive behavior and the level of myocardial enzymes are of great significance for the diagnosis and prognosis analysis of violent behavior in patients with schizophrenia. By detecting changes in these indicators, we can gain a more comprehensive understanding of a patient’s condition and treatment.

Schizophrenia
Myocardial enzyme index
Act of violence
Predict
Violence prediction
Aggressive behavior
Clinical data analysis
Biochemical markers
==== Body
pmc Core Tip: This study analyzes the expression levels of myocardial enzymes in patients with schizophrenia and explores their predictive value for violent behavior. The study involved 288 cases. The study was reviewed and approved by the Shaoxing Seventh Hospital Medical Ethics Committee. Patients with schizophrenia and 100 healthy controls, and patients were divided into violent and non-violent groups based on Modified Overt Aggression Scale scores. The results showed that there was a significant difference in serum myocardial enzyme levels between patients with schizophrenia and healthy individuals, and the myocardial enzyme levels in the violent group were higher than those in the non-violent group. Previous aggressive behavior and myocardial enzyme levels are of great value for diagnosis and prognosis analysis. By monitoring these indicators, we can have a more comprehensive understanding of the patient's condition and treatment progress, providing important references for clinical management.

INTRODUCTION

As a common mental illness, schizophrenia will not only change the patient’s way of thinking and inner emotions in clinic, but also their will and behavior to a certain extent. Such changes may recur frequently, which is a serious mental disorder[1]. Among these, the most typical behavior of patients with schizophrenia is violence[2]. Compared to the healthy population, people with schizophrenia are more prone to violence. On the one hand, because the symptom is extremely difficult to find, and explosive and destructive, it has a certain degree of negative impact on medical staff, patients, and community residents. However, the number of violent acts is increasing annually. Therefore, distinguishing and judging violent acts in time and effectively, and even predicting when violent acts occur, is of great clinical value. Some scholars have suggested that because of their low level of cognition and being controlled by negative emotions and even psychotic symptoms, patients are angry and impulsive, which leads to violent behavior[3]. Patients in the onset stage will not only have emotional instability but also have abnormal behavior operations. Clinical testing and blood analysis has revealed that the activity of myocardial zymogram in patients’ serum has been significantly improved, especially when patients are excited and excited, and myocardial zymogram is even more abnormally increased. No relevant evidence of heart disease has been found for the time being.

MATERIALS AND METHODS

Study population and data collection

A total of 288 patients with schizophrenia admitted to our hospital from February 2023 to January 2024 were selected as the research object of the case group, and 100 healthy people were selected as the control group. The case group comprised 72 males and 88 females aged 22–59 years, with an average age of 43 years ± 6.23 years.

Based on the Modified Overt Aggression Scale (MOAS) score, the case group was further divided into violent (123 cases) and non-violent (165 cases) groups. Among them, the violent and non-violent groups included 30 males and 38 females and 42 males and 50 females, respectively, aged from 21 years to 61 years, with an average of 44 years ± 6.57 years.

Inclusion criteria: (1) The subjects met the diagnostic criteria of schizophrenia or acute schizophrenia-like psychotic disorder in the classification of mental and behavioral disorders in the International Classification of Diseases-10[4]; (2) The subjects were 20-65 years old, regardless of sex; (3) The patients and their families were informed about this study and signed the consent form; (4) The selected patients did not take any antipsychotic drugs for at least two weeks before the study, and had not received electroconvulsive therapy; (5) Both groups were patients with acute episode of schizophrenia; and (6) In the violent group, a history of violent aggression, and definite aggression one week before admission, and the revised MOAS score was ≥ 5[5]. The non-violent group has no violent behavior in the past and now, and the MOAS score is < 5.

The exclusion criteria were as follows: (1) Mental disorders and mental retardation caused by physical or brain diseases; (2) History of alcohol and psychoactive substance abuse; (3) History of traumatic brain injury and loss of consciousness for more than 30 minutes; (4) Audio-visual dysfunction; and (5) Blood or serious infectious diseases.

Sample size calculating

According to the calculation of 10 times the study variables, a total of 24 variables were involved in this study, that is, n = 24 × 10 × 120%= 288, so a total of 288 patients with schizophrenia were selected in this study.

At the same time, according to the formula n = 2 (μα+μβ) δ/β, where β = 0.2, α = 0.5. Finally, n = 100 was obtained, that is, the sample size of the healthy group was 100 cases.

Method

Patients’ general information, including gender, age, marital status, occupational status, drinking history, smoking history, and so on, was collected and regular follow-up conducted.

The fasting venous blood (4 mL) was collected from the two groups, and the sample serum was separated for five minutes by centrifuge at a speed of 5000r/minute. Furthermore, the serum myocardial enzyme spectrum was used for testing, and the operation was carried out in strict accordance with the relevant instructions of the kit. At the same time, the relevant experimental results and index changes were recorded and analyzed in detail. Among them, aspartate transferase (AST) kit was purchased from Shanghai Huzheng Biotechnology Co., LTD., purity: 99%, product number: Hhzt-4582; lactate dehydrogenase (LDH) kit was purchased from Shenzhen Zike Biotechnology Co., LTD., purity: 100%, product number: ZIKER006; creatine kinase creatine kinase (CK) kit was purchased from Shanghai Liemai BioEngineering Co., LTD., purity: 99%, code: LM-876416S; CK isoenzyme (CK-MB) kit was purchased from Guangzhou Orida Biotechnology Co., LTD., purity: 99%, code: ARD11095; A-hydroxybutyrate dehydrogenase (A-HBDH) kit was purchased from Shanghai Fusheng Industrial Co., LTD., purity: 98%, product number: FS14687.

Observation index

During the detection, five important indexes were mainly analyzed, including AST , LDH , CK, CK-MB and A-HBDH; the judgment range of each index was as follows: The normal value of AST was between 8 IU/L and 35 IU/L, the normal range of LDH is 109 IU/L to 245 IU/L, that of CK is 50 IU/L to 190 IU/L, of CK-MB is less than 24 ng/mL, and of A-HBDH is 70 IU/L to 180 IU/L.

Statistical analysis

Statistical Package for the Social Sciences 26.0 was used to analyze the study data. The measurement data were expressed as mean ± SD and t-tested. Counting data is expressed as [n (%)] and χ² test is used. P < 0.05 was considered statistically significant.

RESULTS

Comparison of myocardial enzyme indexes between patients with schizophrenia and healthy people

The indexes of serum myocardial enzymes in schizophrenic patients were higher than those in healthy group, P < 0.05, as shown in Table 1.

Table 1 Detection results of myocardial enzymes in schizophrenic patients and healthy groups

Group	n	Aspartate transferase (IU/L)	Lactate dehydrogenase (IU/L)	Creatine kinase (IU/L)	Creatine kinase isoenzyme (ng/mL)	A-hydroxybutyrate dehydrogenase (IU/L)	
Schizophrenia group	288	49.76 ± 25.56	213.26 ± 40.21	155.23 ± 55.92	22.17 ± 7.64	160.23 ± 30.67	
Health group	100	27.41 ± 12.33	172.71 ± 10.68	100.34 ± 8.37	14.23 ± 2.11	125 ± 6.38	
t value	-	8.406	9.956	9.770	10.250	11.392	
P value	-	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	

Comparison of myocardial enzymes in patients with schizophrenia

The indexes of serum myocardial enzymes in the violent group were higher than those in the non-violent group (P < 0.05), as shown in Table 2.

Table 2 Expression level of myocardial enzymes in patients with different violent behaviors

Group	n	Aspartate transferase (IU/L)	Lactate dehydrogenase (IU/L)	Creatine kinase (IU/L)	Creatine kinase isoenzyme (ng/mL)	A-hydroxybutyrate dehydrogenase (IU/L)	
Violence group	123	75.67 ± 12.46	257.31 ± 15.43	219.34 ± 6.67	29.41 ± 6.23	195.38 ± 3.62	
Non-violent group	165	30.61 ± 12.43	180.71 ± 11.34	107.84 ± 9.37	16.83 ± 2.34	134.24 ± 5.28	
t value	-	30.400	48.566	112.418	23.795	110.493	
P value	-	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	

Single factor analysis of influencing violence

Univariate analysis showed that irritability, previous aggressive behavior, AST, LDH, CK, CK-MB, A-HBDH were significantly related to the violent behavior of schizophrenics (P < 0.05). Gender, marital status, professional status, introversion, involuntary admission, major life events, anxiety, hostility, suspicion, hallucinations, behavioral disorders, drinking history, smoking history, hallucinations, etc. are not significantly related to the occurrence of violent behavior in schizophrenics (P > 0.05), as shown in Table 3.

Table 3 Single factor analysis of influencing violence, n (%)

Factor	Violence group
	Non-violent group	t/χ²	P value	
Gender	Men	54 (43.90)	75 (45.45)	0.069	0.793	
Women	69 (56.10)	90 (54.55)			
Married	65 (52.84)	89 (53.94)	0.034	0.854	
Inoccupation	77 (62.60)	97 (58.79)	0.429	0.513	
Introverted	71 (57.72)	90 (54.55)	0.289	0.591	
Irritability	75 (60.98)	62 (37.58)	15.471	0.000	
Involuntary admission	50 (40.65)	79 (47.88)	1.489	0.222	
Major life events	56 (45.53)	74 (44.85)	0.013	0.909	
Depressed	66 (53.66)	94 (56.97)	0.313	0.576	
Previous aggressive behavior	93 (75.61)	66 (40.00)	36.135	0.000	
Anxious	1.58 ± 0.94	1.65 ± 1.12	0.561	0.575	
Adopt a hostile attitude towards	3.04 ± 1.07	2.87 ± 1.08	1.327	0.186	
Be suspicious	3.65 ± 1.45	3.19 ± 1.56	2.550	0.011	
Hallucination	3.38 ± 1.68	3.15 ± 1.58	1.189	0.235	
Behavior disorder	3.36 ± 1.39	3.14 ± 1.25	1.408	0.160	
Drinking history	54 (43.90)	58 (35.15)	2.271	0.132	
Smoking history	59 (47.97)	61 (36.97)	3.507	0.061	
Number of hospitalization	≤ 3 times	76 (61.79)	119 (72.12)	3.441	0.064	
> 3 times	47 (38.21)	46 (27.88)	
Course of a disease	< 6 months	22 (17.89)	49 (29.70)	5.441	0.066	
6-12months	54 (43.90)	59 (35.76)	
> 12months	47 (38.21)	57 (34.54)	
Personality characteristics	Introvert	40 (32.52)	62 (37.57)	3.409	0.182	
Extroverted	30 (24.39)	26 (15.76)	
Intermediate personality	53 (43.09)	77 (46.67)	
Aspartate transferase (IU/L)	75.67 ± 12.46	30.61 ± 12.43	30.400	< 0.001	
Lactate dehydrogenase (IU/L)	257.31 ± 15.43	180.71 ± 11.34	48.566	< 0.001	
Creatine kinase (IU/L)	219.34 ± 6.67	107.84± 9.37	112.418	< 0.001	
Creatine kinase isoenzyme (ng/mL)	29.41 ± 6.23	16.83 ± 2.34	23.795	< 0.001	
A-hydroxybutyrate dehydrogenase (IU/L)	195.38 ± 3.62	134.24 ± 5.28	110.493	< 0.001	

Multivariate analysis

Taking whether schizophrenic patients have violent behavior as the dependent variable Y (non-violent group = 0, violent group = 1), logistic multivariate regression analysis shows that aggressive behavior, AST, CK and CK-MB are independent risk factors for schizophrenic patients to have violent behavior (P < 0.05), as shown in Table 4.

Table 4 Logistic multivariate analysis of violent behavior in schizophrenic patients

Variable	B	SE	Wals	P value	Exp(B)	95%CI		
Irritability	0.388	0.991	0.153	0.696	1.474	0.211	10.286	
Previous aggressive behavior	1.117	0.564	3.920	0.048	3.054	1.011	9.225	
Aspartate transferase (IU/L)	0.169	0.021	63.748	0.000	1.184	1.136	1.235	
Lactate dehydrogenase (IU/L)	-0.029	0.035	0.678	0.410	0.971	0.906	1.041	
Creatine kinase (IU/L)	0.091	0.032	8.239	0.004	1.095	1.029	1.165	
Creatine kinase isoenzyme (ng/mL)	0.373	0.093	16.009	0.000	1.452	1.210	1.744	
A-hydroxybutyrate dehydrogenase (IU/L)	0.042	0.113	0.138	0.711	1.043	0.835	1.302	
Constant	-19.685	22.600	0.759	0.384	0.000			

ROC verification

Receiver operating characteristic (ROC) results showed that the areas under the curve of previous aggressive behavior, AST, CK and CK-MB expression levels were 0.650, 0.930, 0.913 and 0.909 respectively, and the corresponding sensitivities were 72.40%, 89.40%, 91.10% and 87.80% respectively (Table 5 and Figure 1).

Figure 1 Receiver operating characteristic curve of violent behavior in patients with schizophrenia caused by previous aggressive behavior and serum myocardial enzyme level. AST: Aspartate transferase; CK: Creatine kinase; CK-MB: Creatine kinase isoenzyme.

Table 5 Diagnostic value analysis

Index	Areas under the curve	Sensitivity	Specificity	95%CI	Youden's index	
Previous aggressive behavior	0.650	72.40	57.60	0.586-0.714	0.300	
Aspartate transferase (IU/L)	0.930	89.40	89.70	0.899-0.962	0.791	
Creatine kinase (IU/L)	0.913	91.10	93.30	0.874-0.952	0.844	
Creatine kinase isoenzyme (ng/mL)	0.909	87.80	87.30	0.872-0.947	0.751	

DISCUSSION

As one of the common mental disorders, schizophrenia has different symptoms in each disease period, and different clinical types have their own symptoms[6], among which cardiovascular symptoms are more common. Because of the long course of the patient and the side effects of long-term medication, the serum myocardial enzyme activity of patients with schizophrenia is abnormal, and the illness and drug factors have a certain impact on the body of such patients with schizophrenia, which makes most patients exhibit violence and aggression[7]. Related research[8] indicates that the rate of violent behavior of mental patients in China is as high as 50%, which seriously threatens the personal safety of family members and medical staff.

This study compared the levels of serum myocardial enzymes in patients with schizophrenia and healthy people. The results revealed that the indexes of serum myocardial enzymes in patients were higher than those in healthy individuals. At the same time, whether patients with schizophrenia exhibited violent behavior was compared again. The results revealed that the indexes of serum myocardial enzymes in patients with violence were higher than those in patients without violence. Univariate analysis established that gender, introversion, major life events, and so on are the influencing factors of violent behavior in patients with schizophrenia. The reason analysis reveals differences between men and women in terms of physiological structure, hormone level and gene expression, which affects mood, behavior and cognitive function, and then affects the behavior performance of patients[9]. For unemployed individuals with schizophrenia, the lack of stable work and social activities limits their social skills and stress resistance, so that when faced with challenges or difficulties, they will be more inclined to take violent actions to deal with them[10]. At the same time, patients with introverted personality tend to be alone, which will lead to social isolation and loneliness, while patients with schizophrenia suffer from social discrimination, which further increases their psychological pressure and anxiety, and eventually leads to violence as a coping mechanism[11]. In addition, when patients experience major life events, such as the death of their loved ones and family breakdown, they will not only experience intense emotional trauma and psychological pressure, but their psychological state will also be affected, thus inducing or aggravating the symptoms of schizophrenia and further aggravating the risk of violent behavior[12]. In addition, depression will make patients with schizophrenia feel depressed, lose interest, lose energy, and other symptoms, thereby leading to their loss of confidence and enthusiasm for life. Furthermore, depression will further aggravate patients’ hallucinations, delusions, and other symptoms, resulting in strong anxiety and fear of the surrounding environment, which will lead to irritability and impulsiveness, and violent actions to deal with their inner fears and anxieties[13].

Aggressive behavior is often closely related to individual psychological characteristics and behavioral patterns. For patients with schizophrenia, aggressive behaviors may have been present in the past, which means that patients are more inclined toward violence when they are in trouble[14]. Once this behavior pattern is formed, similar situations in the future may trigger such behavior, thus increasing the risk of violent behavior[15]. The results of this study indicate that people with schizophrenia who have exhibited aggressive behavior in the past are more likely to lead to violent behavior. Logistic regression analysis established that aggressive behavior in the past is an independent risk factor leading to violent behavior in patients with schizophrenia. Reason analysis indicates that aggressive behavior in the past reflects patients’ psychological obstacles, including emotional instability, impulse control obstacles, social skills defects, and so on. These problems increase the risk of violent behavior to a certain extent[16], and when patients with schizophrenia have fantasies, delusions, and other symptoms, they may further aggravate these psychological problems[17]. At the same time, patients’ social relations and the surrounding environment have a negative impact, which will aggravate patients’ psychological pressure and troubles to a certain extent, thus making them more prone to aggressive behavior[18]. Therefore, patients who have already experienced violent behavior should take appropriate measures in time.

Because the serum myocardial enzyme activity of patients with schizophrenia will be abnormal, and myocardial enzyme is mainly distributed in skeletal muscle and myocardium, this is an important index to reflect myocardial damage[19]. When myocardial injury occurs, it can be released into the blood, which increases the corresponding enzyme activity in the blood, mainly related to the pathological changes of the brain nervous system and neuromuscular and biochemical immune system dysfunction[20]. This study documents that the contents of AST, CK and CK-MB in the violent group are significantly higher than those in the non-violent group, which indicates that the contents of AST, CK and CK-MB in the body are closely related to the severity of irritability, aggressive behavior, and schizophrenia symptoms. Further logistic regression analysis revealed that serum myocardial zymogram is an independent risk factor for violent behavior in patients with schizophrenia. The reason for this is that when psychotics are excited and aggressive, the sympathetic nerve of the body is excited, which increases the level of catecholamine hormones, thus stimulating the contraction of blood vessels in the whole body, causing ischemia and hypoxia in various organs and tissues[21]. This not only reduces the energy metabolism level of tissues and cells to a certain extent, but also increases the permeability of the tissue cell membrane, promotes CK to enter the blood circulation from cells, and leads to an increase in the level of serum CK[22]. At the same time, owing to the influence of the physiological, psychological environment, and social factors, patients with schizophrenia may experience brain dysfunction, which may affect mental activities such as cognition, consciousness, and emotion[23]. Since the clinical symptoms of patients with schizophrenia are not obvious at the initial stage of onset, disease progression is slow. With the recurrence of the disease and the aggravation of symptoms, patients are prone to impulsive behavior. To a certain extent, the body’s energy metabolism is vigorous and muscle movement is intense, which leads to a significant increase in the activities of myocardial enzymes such as AST, CK, and CK-MB, and the patient’s behavioral activities are closely related to the increase in CK levels[24]. In addition, when the patient exhibits violent behavior, the muscle tension of the skeletal muscles is significantly enhanced, which destroys the structure of tissue cells and damages muscle cells, thus increasing the level of serum myocardial enzymes[25].

ROC analysis of previous aggressive behavior and serum myocardial enzymes is of high value in predicting and evaluating violent behavior in patients with schizophrenia, and serum AST, CK, and CK-MB levels can be used as markers to evaluate their prognostic value.

CONCLUSION

In summary, a close relationship exists between the aggressive behavior of patients with schizophrenia in the past and the violent behavior of serum myocardial enzymes. However, although the relationship between myocardial enzyme levels and aggression has been identified in this study, further longitudinal studies are needed to investigate the causal relationship. At the same time, the serological indicators and biochemical markers of the results of this study will provide certain references for the diagnosis and treatment of aggressive behavior in schizophrenia patients, but the specific mechanisms of these biochemical indicators in the intervention methods and prognostic effects still need to be further studied. This also becomes the shortcoming of this study.

Data sharing statement

No additional data are available.

Institutional review board statement: The study was reviewed and approved by the Shaoxing No.7 Hospital Medical Ethics Committee.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Psychiatry

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade C, Grade C

Novelty: Grade B, Grade B

Creativity or Innovation: Grade B, Grade C

Scientific Significance: Grade B, Grade B

P-Reviewer: Oakley BFM; Taylor WD S-Editor: Luo ML L-Editor: A P-Editor: Yu HG
==== Refs
1 Jauhar S Johnstone M McKenna PJ Schizophrenia Lancet 2022 399 473 486 35093231
2 Whiting D Gulati G Geddes JR Fazel S Association of Schizophrenia Spectrum Disorders and Violence Perpetration in Adults and Adolescents From 15 Countries: A Systematic Review and Meta-analysis JAMA Psychiatry 2022 79 120 132 34935869
3 Ballesteros J Moreno-Calvete MC Santos-Zorrozúa B González-Fraile E Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia Cochrane Database Syst Rev 2023 7 CD013511 37490701
4 Cheniaux E Landeira-Fernandez J Versiani M The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10 Psychopathology 2009 42 293 298 19609099
5 Michel JS Pace VL Edun A Sawhney E Thomas J Development and validation of an explicit aggressive beliefs and attitudes scale J Pers Assess 2014 96 327 338 24033293
6 Skokou M Messinis L Nasios G Gourzis P Dardiotis E Cognitive Rehabilitation for Patients with Schizophrenia: A Narrative Review of Moderating Factors, Strategies, and Outcomes Adv Exp Med Biol 2023 1423 193 199 37525044
7 Hu ZR Yang ZZ Wang XB Chu HS Liu CX Case report: Amisulpride therapy induced reversible elevation of creatine kinase-MB and bradycardia in schizophrenia Front Psychiatry 2022 13 1037738 36590617
8 Youn S Guadagno BL Byrne LK Watson AE Murrihy S Cotton SM Systematic Review and Meta-analysis: Rates of Violence During First-Episode Psychosis (FEP) Schizophr Bull 2024 50 757 770 38412435
9 Seeman MV González-Rodríguez A Stratification by Sex and Hormone Level When Contrasting Men and Women in Schizophrenia Trials Will Improve Personalized Treatment J Pers Med 2021 11 929 34575706
10 Gong M Yao L Ge X Liu Z Zhang C Yang Y Amdanee N Wang C Zhang X Empathy deficit in male patients with schizophrenia and its relationships with impulsivity and premeditated violence Front Psychiatry 2023 14 1160357 37398588
11 Tillman B Smith E Cho A Kennington C Kreis A Through the Cracks: The Disposition of Patients With Schizophrenia Spectrum Disorders in the Post-Asylum Era HCA Healthc J Med 2022 3 85 88 37424604
12 Paulus FW Ohmann S Möhler E Plener P Popow C Emotional Dysregulation in Children and Adolescents With Psychiatric Disorders. A Narrative Review Front Psychiatry 2021 12 628252 34759846
13 Orzelska-Górka J Mikulska J Wiszniewska A Biała G New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression Int J Mol Sci 2022 23 10624 36142523
14 Jones C Hacker D Cormac I Meaden A Irving CB Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia Cochrane Database Syst Rev 2010 4 CD008712
15 Fekih-Romdhane F Maktouf H Cheour M Aggressive behaviour in antipsychotic-naive first-episode schizophrenia patients, their unaffected siblings and healthy controls Early Interv Psychiatry 2023 17 299 310 35712845
16 Winter-van Rossum I Weiser M Galderisi S Leucht S Bitter I Glenthøj B Hasan A Luykx J Kupchik M Psota G Rocca P Stefanis N Teitelbaum A Bar Haim M Leucht C Kemmler G Schurr T EULAST Study Group, Davidson M, Kahn RS, Fleischhacker WW Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST) Lancet Psychiatry 2023 10 197 208 36716759
17 Yıldız E Yıldırım Ö The mediating role of psychological flexibility in the relationship between psychotic symptom severity and depression in individuals diagnosed with schizophrenia J Psychiatr Ment Health Nurs 2024
18 Pan Y Wen Y Jin J Chen J The interpersonal computational psychiatry of social coordination in schizophrenia Lancet Psychiatry 2023 10 801 808 37478889
19 Li ZP You YS Wang JD He LP Underlying disease may increase mortality risk in users of atypical antipsychotics World J Psychiatry 2022 12 1112 1114 36158300
20 Halawa N Armstrong M Fancy S Abidi S Clozapine-induced myocarditis and subsequent rechallenge: a narrative literature review and case report J Can Acad Child Adolesc Psychiatry 2023 32 e252 e263 38034406
21 Ball J Darby I Mental health and periodontal and peri-implant diseases Periodontol 2000 2022 90 106 124 35913583
22 Edinoff AN Mohammad-Amin H Odisho AS Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status Health Psychol Res 2022 10 37530 35999974
23 Williams JA Burgess S Suckling J Lalousis PA Batool F Griffiths SL Palmer E Karwath A Barsky A Gkoutos GV Wood S Barnes NM David AS Donohoe G Neill JC Deakin B Khandaker GM Upthegrove R PIMS Collaboration Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders: A Mendelian Randomization Study JAMA Psychiatry 2022 79 498 507 35353173
24 Yuksel C Chen X Chouinard VA Nickerson LD Gardner M Cohen T Öngür D Du F Abnormal Brain Bioenergetics in First-Episode Psychosis Schizophr Bull Open 2021 2 sgaa073 33554120
25 Xiong X Hou L Park YP Molinie B GTEx Consortium, Gregory RI, Kellis M Genetic drivers of m(6)A methylation in human brain, lung, heart and muscle Nat Genet 2021 53 1156 1165 34211177
